MyMedicalRecords Wins Appeal to Proceed to Collect $30

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MyMedicalRecords Wins Appeal to Proceed to Collect $30 Million From Surgery Center Management

LOS ANGELES, CA--(Marketwired - Jul 2, 2013) - MMRGlobal, Inc. ( OTCQB : MMRF ), through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, "MMR"), today announced that pursuant to an order dated July 1, 2013, the Appellate Court dismissed an appeal by Surgery Center Management, LLC ("SCM") filed May 17, 2012. Accordingly, the case will be remanded back to Superior Court where MMR will pursue its claim for breach of contract against SCM, seeking as much as $30 million in damages. The appeal was filed in the Second Appellate District, Division Eight. The decision of the Court was decided without oral argument by the parties giving MMR a green light to move forward with the case in the trial court. The Court of Appeal ruled on the written briefs alone which MMR believes vindicates its position that there never was a valid basis for the appeal and it was nothing more than a stalling tactic by SCM. 

According to Robert H. Lorsch, MMRGlobal CEO, "MyMedicalRecords looks forward to proceeding with the case on the merits before the Los Angeles Superior Court where we will pursue claims for breach of contract, seeking as much as $30 million in damages. MMR believes there is no viable defense to SCM's breach of the agreement at issue. As of this date, SCM already owes MMR more than $15 million, plus interest and penalties."

The case stems from a December 9, 2011 Non-Exclusive Settlement and Patent License Agreement ("Agreement") whereby SCM contracted to pay MMR an initial payment of $5 million payable on December 23, 2011, and additional payments of $5 million per year for five consecutive years, to license certain of MMR's health IT and Personal Health Record patents covering uses of MMR's personal and professional health IT products and services. On January 19, 2012, MyMedicalRecords, Inc. filed a lawsuit in the Superior Court of the State of California for the County of Los Angeles for breach of contract and damages in an amount of $30 million. On September 19, 2012, the Company engaged the law firm of Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP ("Liner") to represent MMR in the matter. The Agreement contains an arbitration clause, and non-binding arbitration proceedings have been completed. However, SCM filed an appeal pertaining to the Arbitration provision anyway which MMR learned it won yesterday, July 1 st .

MMR believes its claim against SCM continues to be collectible based on a series of publicized settlements involving SCM pertaining to other matters. MMR also believes that SCM and affiliates of SCM continue to operate throughout California and other parts of the United States. As of this date, SCM has a past due balance of nearly $15 million owed to MMR including interest and penalties. The Agreement between MMR and SCM also includes the settlement of any potential claims by MMR against SCM and its affiliates for any past patent infringement. 

MMR is a leading provider of Personal Health Records ("PHRs"), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals . MMR currently has seven U.S. health information technology (HIT) patents and continuation applications and pending patents covering inventions pertaining to Personal Health Records, Patient Portals and other Electronic Health Record systems. On June 19, 2013, MMR received a Notice of Allowance, application number 13/714,720, from the United States Patent and Trademark Office entitled "Method for Providing a User with a Service for Accessing and Collecting Prescriptions," which will become MMR's eighth patent in its U.S. health IT patent portfolio. The Company also has HIT patents issued or pending in 12 other countries of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, South Korea, Israel, and European nations. Additionally, MMR acquired biotechnology intellectual property separate from its health IT portfolio as a result of a reverse merger with Favrille, Inc., a biopharmaceutical company, in January 2009. After investing more than $100 million in research and development on its FavId™/Specifid™ vaccine trials and use of customized tumor cells to treat lymphoma patients and other technologies. MMR's biotech assets include an extensive portfolio including its anti-CD20 monoclonal antibodies, data from vaccine trials, thousands of patient tumor samples, and other intellectual property which MMR has already licensed to a major pharmaceutical company under a $13 million non-exclusive licensing agreement .

About MMRGlobal MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro , is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com . View demos and video tutorials of the Company's products and services at www.mmrtheater.com .

Forward-Looking Statements All statements in this press release that are not strictly historical in nature, whether or not such statement relates directly to Surgery Center Management, LLC, and including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

CONTACT: Michael Selsman Public Communications Co. ms@publiccommunications.biz (310) 922-7033

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 161

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 24

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 12

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 90

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 299

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 72

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 58

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 109

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 56

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 51

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Planning for Long-Term and Short-Term Financial Success

Updated Category Investing Views 1297

Financial success rarely happens by accident. It requires deliberate planning, disciplined execution, and ongoing adjustments to align with changing circumstances. People often focus either on their short-term needs or their long-term goals, overlooking the importance of balancing them. A strong financial strategy incorporates immediate priorities while building a secure...

Continue Reading
Anticipating Caesars Entertainment's Upcoming Earnings Report

Updated Category News Views 259

A Look Ahead at Caesars Entertainment's Earnings Report Caesars Entertainment (NASDAQ: CZR) is on the verge of revealing its quarterly earnings report, drawing the interest of investors and market analysts alike. With anticipation building, here’s what the market expects before the announcement. Projected Earnings and Market Reactions Market analysts predict that...

Continue Reading
ResVita Bio's FDA Meeting Marks Progress for Netherton Syndrome

Updated Category News Views 215

ResVita Bio Advances Clinical Plans for Netherton Syndrome ResVita Bio, a biotechnology company focused on groundbreaking treatment options for skin diseases, recently shared exciting news about a pivotal meeting with the U.S. Food and Drug Administration (FDA). This engagement was crucial as it involved RVB-003, their leading investigational therapy targeted at...

Continue Reading
Solidion Technology Innovates to Advance Lithium-Sulfur Batteries

Updated Category News Views 235

Solidion Technology Makes Significant Advances in Battery Technology Solidion Technology, Inc. (NASDAQ: STI) has made remarkable progress in the field of battery technology, particularly with its lithium-sulfur (Li-S) batteries. Recently, Solidion announced a breakthrough in achieving a cell energy density of 380 Wh/kg, with future ambitions set at reaching 450 Wh/kg....

Continue Reading
Luray Peanut Co. Spices Up Snack Market with New Launch

Updated Category News Views 76

Spice Meets Peanut In An Unexpected Fusion Alright, let's shed some light on the latest concoction shaking up the snacking aisle. Luray Peanut Company has teamed up with none other than Texas Pete® to create a spicy new twist on boiled peanuts. Trust me, this is no typical snack partnership. Instead, it's the kind of daring venture that screams Southern soul with a...

Continue Reading